Difference between revisions of "Part:BBa K3897000:Design"

 
 
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
1
 
−
 
  
 +
The aptamer is obtained from previous literature, in which it is selected by SELEX using the epitope of HER2<sup>[1]</sup>.
  
 
===Source===
 
===Source===
−
 
+
The aptamer is obtained from previous literature, in which it is selected by SELEX using the epitope of HER2<sup>[1]</sup>.
−
1
+
  
 
===References===
 
===References===
 +
<ol start='' >
 +
 +
<li>Liu, Z., Duan, J. H., Song, Y. M., Ma, J., Wang, F. D., Lu, X., &amp; Yang, X. D. (2012). Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. Journal of translational medicine, 10, 148. <a href='https://doi.org/10.1186/1479-5876-10-148' target='_blank' class='url'>https://doi.org/10.1186/1479-5876-10-148</a></li>
 +
 +
</ol>

Latest revision as of 02:23, 5 October 2021


HR2 Aptamer, for targeting HER2 receptors


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The aptamer is obtained from previous literature, in which it is selected by SELEX using the epitope of HER2[1].

Source

The aptamer is obtained from previous literature, in which it is selected by SELEX using the epitope of HER2[1].

References

  1. Liu, Z., Duan, J. H., Song, Y. M., Ma, J., Wang, F. D., Lu, X., & Yang, X. D. (2012). Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. Journal of translational medicine, 10, 148. <a href='https://doi.org/10.1186/1479-5876-10-148' target='_blank' class='url'>https://doi.org/10.1186/1479-5876-10-148</a>